Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study.

@article{Mukhopadhyay2006Phosphodiesterase5II,
  title={Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study.},
  author={Saibal Mukhopadhyay and Manish Sharma and S. S. Ramakrishnan and J Tuty L Yusuf and Mohit Dayal Gupta and Naveen Bhamri and Vijay Trehan and Sanjay Tyagi},
  journal={Circulation},
  year={2006},
  volume={114 17},
  pages={1807-10}
}
BACKGROUND Phosphodiesterase-5 inhibitors produce a significant decrease in pulmonary vascular resistance in patients with idiopathic pulmonary arterial hypertension. We studied the effects of tadalafil, a phosphodiesterase-5 inhibitor, on short-term hemodynamics, tolerability, and efficacy over a 12-week period in patients of Eisenmenger syndrome having a… CONTINUE READING